Why the study?
What are the trends and variations in oral anticoagulant choice among incident OAC users with nonvalvular AF between 2010 and 2017?
What are the trends and variations in oral anticoagulant choice among incident OAC users with nonvalvular AF between 2010 and 2017?
Between 2010 and 2017, NOAC prescriptions increased substantially for nonvalvular AF, with apixaban driving the increase, though warfarin and apixaban remained preferred for elderly and higher-risk patients.
Shifts in OAC choice for nonvalvular AF merit outcome surveillance; leaves open optimal selection in elderly, higher-risk patients.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: